In the case of most progressive illnesses, early detection is key, and this is particularly true for both primary types of lung cancer, NSCLC and SCLC (non-small cell lung cancer and small cell lung cancer), as well as the “Super Bug” known as MRSA (Methicillin-resistant Staphylococcus aureus). MRSA, a kind of robust and highly persistent staph bacterium, is a major, growing concern for hospitals, due in large part to this nasty little bug’s ability to shrug off the most powerful antibiotics available today. Whether a given infection is technically classified as a CA-MRSA (community-acquired) or HA-MRSA (hospital-acquired), the patient end point is invariably a healthcare facility, where the bug may spread and/or lie dormant, posing a serious propagation threat, both for patients and healthcare professionals alike.
Surgical site infection (SSI) continues to be one of the most dangerous postoperative complications, accounting for roughly one third of all HAI’s (hospital-acquired infections) and of that approximately 33% of all HAI’s, nearly 30% are MRSA-positive. MRSA loves to live in the skin and is often hiding in places like the nose, throat and armpits of carriers, making successful decolonization of a given subject extremely tricky. Decolonization requires prolonged treatments, like 5 to 10 days of twice-daily mupirocin in the nose, oral rinsing with 0.2% chlorhexidine three times a day for a week to try and clear the throat, or dilute bleach baths for as long as three months in order to decontaminate carriage sites on the body.
The global HAI testing market ran about $2.2B just two years prior and was recent forecast by Transparency Market Research as topping out around $7.5B in 2019, on a CAGR of roughly 19.3%, making this a huge target for developers and an area of considerable interest for investors as well. The ability to test early and actually prevent more serious/costly issues is an extremely attractive approach for curbing the soaring overall healthcare cost impacts to various economies, making the emergence of detection devices a highly sought-after possibility.
NSCLC lung cancer accounts for as much as 90% of all cases and the global market for just drugs to treat such cancer is on-track to hit around $6.9B by 2019 on a 4.84% CAGR, with the broader therapy market being much larger and on-track to hit around $7.9B by 2020 (GBI Research). With a projected CAGR somewhere in the neighborhood of 6.6%, as new drugs and premium therapies, like second-line and squamous cell treatment continue to emerge and offset generic chemotherapies, the NSCLC treatment market is growing just as fast as a malignant cancer itself. The biggest players like AstraZeneca (NYSE:AZN), Roche (OTCQX: RHHBY) and Merck (NYSE: MRK) will continue to drive the trend towards market segmentation in lung cancer treatment with premium therapies and new drugs, according to GBI Research.
The recent announcement by Zenosense, Inc. (OTCQB: ZENO), which is currently developing two types of electronic nose devices via contract with Zenon Biosystem that continuously monitor for and accurately discriminate hallmark VOCs (volatile organic compounds) of key MRSA and lung cancer biomarkers, that their common stock has been approved by the DTC (Depository Trust Corporation) for DWAC/FAST transfer, makes this small sector up-and-comer even more attractive as a vehicle for investors to tap into these markets. As a developer of detection devices that could save lives while grabbing market share from the treatment end of the game, ZENO’s technology is disruptive and could change the entire MRSA/SA and lung cancer markets on a fundamental level. DWAC/FAST transfer approval of the company’s common stock, using ZENO’s transfer agent, Action Stock Transfer Corporation, confers considerable benefits to shareholders as well. Including rapid brokerage account deposits and withdrawals, elimination of risk associated with handling physical certificates, and the higher liquidity that comes along with such enhanced share accessibility/availability.
Zenosense announced manufacturing of their pre-commercial prototype lung cancer detector early last month (November 4), highlighting key features like the device’s ability to rapidly discriminate against background VOCs in the breath of patients and hone in on the target lung cancer VOC biomarkers. Development partner Zenon Biosystem has come up with some cunning adaptations of the detection pipeline, using molecular sieves in complementary layered and mixed sensor structures, and has developed new metal oxide materials and combinations of metal oxides not found anywhere in the commercially available sensor market today.
Similar breakthroughs in the development of the company’s MRSA detector, including novel biomarker micro-separator sensor technology, has led to testing of a prototype to measure and contrast cultures of MRSA and SA, with a subsequent announcement in late October that the device successfully achieved a sensibility detection rate on cultured headspace in a clinical setting of over 95% during a two-week testing period. The considerable progress ZENO has made in a relatively short time towards commercialization of such highly accurate early detection devices for lung cancer and MRSA/SA could potentially revolutionize the approach to both maladies and saves countless lives.
Given the 224k or so new cases of lung cancer in the U.S. alone each year (around 160k deaths, American Cancer Society) and CDC’s best estimates that 33% of Americans are staph carriers, with 10.8k deaths in the each year from staph, 5.5k of which are MRSA related, there is a massive target market for ZENO’s detection systems.
For more information on Zenosense, please visit: www.zenosense.net
Let us hear your thoughts: Zenosense, Inc. Message Board